Stockreport

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Gain Therapeutics, Inc.  (GANX) 
PDF Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of [Read more]